Nasasinutab (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride, the active ingredient in Nasasinutab, is an alpha‑adrenergic agonist presented as a nasal spray for topical nasal use. It relieves nasal congestion associated with the common cold, sinusitis, and allergic rhinitis by constricting swollen nasal blood vessels.

GNH USA supplies Nasasinutab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality manufacturing and regulatory compliance across global markets.

Xylometazoline Hydrochloride is a topical nasal decongestant that reduces mucosal swelling in upper‑respiratory conditions.

- Common cold: alleviates nasal congestion by shrinking swollen nasal passages. - Sinusitis: reduces nasal blockage, improving sinus drainage. - Allergic rhinitis: eases congestion caused by allergic inflammation.

Adverse reactions are generally mild and related to local nasal irritation.

Common Side Effects: - Burning sensation in the nose - Nasal dryness or crusting - Sneezing or mild irritation - Headache - Altered taste perception - Mild epistaxis (nosebleed)

Serious or Rare Side Effects: - Severe hypertension or cardiovascular strain - Rebound nasal congestion with prolonged use - Nasal ulceration or septal perforation - Allergic reaction (rash, swelling, difficulty breathing) - Cardiac arrhythmia - Persistent nasal bleeding

Use Nasasinutab according to label instructions and avoid exceeding recommended duration.

- Duration limit: Do not use for more than 3‑5 consecutive days to prevent rebound congestion. - Age restriction: Not recommended for children under 6 years unless directed by a healthcare professional. - Cardiovascular caution: Avoid in patients with uncontrolled hypertension or severe heart disease. - Drug interactions: Use cautiously with other nasal decongestants or systemic sympathomimetics. - Pregnancy and lactation: Consult a physician before use, as safety data are limited. - Store at room temperature: Keep in the original container, protect from moisture and direct heat.

Xylometazoline may interact with other agents that affect vascular tone or blood pressure.

Major Interactions (Avoid):\n- Concurrent use of other nasal decongestants: risk of excessive vasoconstriction and hypertension. - Systemic sympathomimetic drugs (e.g., pseudoephedrine): may amplify cardiovascular effects. - Monoamine oxidase inhibitors (MAOIs): potential for hypertensive crisis.

Moderate Interactions (Monitor Closely): - Antihypertensive medications: may reduce their efficacy. - Antidepressants (SSRIs, SNRIs): monitor for increased blood pressure. - Beta‑blockers: possible attenuation of decongestant effect. - Herbal stimulants (e.g., ephedra): watch for additive sympathomimetic activity.